Loading...
•
Sep 30, 2021
IRadimed Q3 2021 Earnings Report
Reported revenue increase and net income growth due to revenue increase.
Key Takeaways
iRadimed Corporation announced financial results for Q3 2021, with revenue of $10.9 million and net income of $2.6 million, or $0.20 per diluted share. Non-GAAP net income was $2.8 million, or $0.23 per diluted share.
Reported revenue of $10.9 million compared to $7.7 million for the third quarter 2020.
Net income was $2.6 million, or $0.20 per diluted share, compared to $1.1 million, or $0.09 per diluted share for the third quarter 2020.
Non-GAAP net income was $2.8 million, or $0.23 per diluted share.
Free cash flow was $3.2 million, compared to $1.3 million for the third quarter 2020.
Revenue by Geographic Location
Forward Guidance
The Company expects to report revenue of $11.5 million to $11.7 million for Q4 2021, GAAP diluted earnings per share of $0.17 to $0.18, and non-GAAP diluted earnings per share of $0.20 to $0.21.
Positive Outlook
- Expects Q4 revenue of $11.5 million to $11.7 million
- Expects Q4 GAAP diluted earnings per share of $0.17 to $0.18
- Expects Q4 non-GAAP diluted earnings per share of $0.20 to $0.21
- Increased full-year revenue guidance to $41.4 million to $41.6 million
- Increased full-year GAAP diluted earnings per share guidance to $0.60 to $0.61
Challenges Ahead
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax
- Continued uncertainties of COVID
- Potential disruptions in limited supply chain
- Reliance on a limited number of products
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...